FDA grants Keytruda and Lenvima combination therapy to treat patients with advanced, non-reprectoable hepatocellular carcinoma

today, MSD and Eisai jointly announced that the u.SFDA(http://has awarded Keytruda and Lenvima breakthrough therapies for advanced, non-reprecentable patients with advanced, non-reprecision in first-line treatmentKeytruda is a heavy-duty PD-1 inhibitor developed by the(http://of Mercado, and Lenvima is an oral protein kinase inhibitor developed by WesfarmersAbout Keytruda
PD-1 inhibitor Keytruda has been approved by the FDA to treat more than 10 cancer synods such as non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck cancer, hepatocellular carcinoma (hepatocellular cancer) who have previously received targeteddrug(http://soraibfen treatment), kidney cancer and more than 10 other cancer syllomasIn July 2018, Keytruda (Korida, Pablo Pearl monoantigen) was approved in China to treat patients with non-reprecision or metastatic melanoma who failed first-line treatment, becoming the first PD-1 inhibitor drug in China to treat advanced melanomaIn March 2019, Keytruda was approved in China for the first-line treatment of EGFR and ALK-negative metastatic non-squamous non-small cell lung cancerAbout Lenvima
Lenvima, an oral tyrosine kinase inhibitor, was approved by the FDA in June 2018 for first-line treatment of patients with unable-to-be-removed hepatocellular carcinoma, becoming the first new system therapy for liver cancer in a decadeOn September 5, 2018, China's StateMedicines(http://Regulatory Authority approved Lenvima (Leweima, methane latinib) single-drug treatment for patients with non-reprecision liver cancer who have not received systematic treatmentIn March 2018, Moshadon and Wesson partnered to expand Lenvima's indications and explore the effects of its combination with Keytruda in treating a range of cancer typesUnder the agreement, The two companies will jointly launch a new clinicaltrial(http://to assess the effectiveness of Lenvima and Keytruda combination therapies in treating six different cancers (endometrial cancer, non-small cell lung cancer, hepatocellular carcinoma, head and neck cancer, bladder cancer and melanoma)